BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 15, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Cancer

Avstera to use funding to advance cancer programs for solid tumors

Nov. 10, 2022
Avstera Therapeutics Corp. has completed a seed round of US$4.55 million to advance its lead cancer programs targeting solid tumors.
Read More
Brain with puzzle piece removed

NRG closes £16M series A to fund fight against neurodegenerative diseases

Nov. 9, 2022
By Nuala Moran
NRG Therapeutics Ltd. has closed a £16 million (US$18.3 million) series A round to take forward programs in Parkinson’s disease and amyotrophic lateral sclerosis, after pinning down the target of its brain penetrant small molecules.
Read More

Financings for Nov. 9, 2022

Nov. 9, 2022
Biopharmas raising money in public or private financings, including: Athersys, Neurobo.
Read More

Scientech Medical raises $72M in Hong Kong listing

Nov. 8, 2022
By Doris Yu
Lepu Scientech Medical Technology (Shanghai) Co. Ltd. raised HK$567 million (US$72.2 million) in a Hong Kong initial public offering. Its shares opened at HK$29.8 apiece, increased over 2% in the middle of the day and closed at HK$29.15 on Nov. 8.
Read More

Financings for Nov. 8, 2022

Nov. 8, 2022
Biopharmas in Asia-Pacific raising money in public or private financings: Meletios.
Read More
Botanical drug illustration

Sensorium raises $30M in series A round to probe plants, fungi for psychoactive natural products

Nov. 8, 2022
By Cormac Sheridan
Sensorium Therapeutics Inc. closed a $30 million series A round to fund the discovery and development of new psychiatric drugs, inspired by human ethnobotanical practices that date back hundreds or even thousands of years.
Read More
Glass yen/yuan symbol

Beihai Biotech nets nearly ¥200M to support core asset development

Nov. 8, 2022
By Doris Yu
Zhuhai Beihai Biotech Co. Ltd. has raised nearly ¥200 million (US$27.5 million) in a series B round slated to support clinical trials for its lead candidates as well as preparations to file an NDA for its core asset, BH-009.
Read More

Financings for Nov. 8, 2022

Nov. 8, 2022
Biopharmas raising money in public or private financings, including: Athersys, Juvena, Marinus, Roivant, Zenas.
Read More

Financings for Nov. 7, 2022

Nov. 7, 2022
Med-tech firms raising money in public or private financings, including: Osler Diagnostics.
Read More

Financings for Nov. 7, 2022

Nov. 7, 2022
Biopharmas raising money in public or private financings, including: Biora, Hc, Nrx.
Read More
Previous 1 2 … 334 335 336 337 338 339 340 341 342 … 677 678 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Purple molecules

    Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

    BioWorld
    Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
  • 3D illustration of a nerve cell

    Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

    BioWorld
    Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing